Calcipotriol

Generic Name: Calcipotriol

Brand Names: Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 112965-21-6

Unique Ingredient Identifier: 143NQ3779B

Background: Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Indication: For the treatment of moderate plaque psoriasis in adults.

Associated Conditions: Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)

Clinical Trials

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Calcipotriene 0.005% Foam

First Posted Date: 2012-04-23

Last Posted Date: 2019-01-22

Lead Sponsor: Mayne Pharma International Pty Ltd

Target Recruit Count: 36

Registration Number: NCT01582932

Locations: 🇺🇸
Investigational Site, Tacoma, Washington, United States

Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Calcipotriene 0.005% Foam

First Posted Date: 2012-03-26

Last Posted Date: 2018-05-11

Lead Sponsor: Mayne Pharma International Pty Ltd

Target Recruit Count: 18

Registration Number: NCT01563068

Locations: 🇺🇸
Investigational Site, Houston, Texas, United States

LEO 90100 in the Treatment of Psoriasis Vulgaris

Phase 2

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: LEO 90100
Drug: Betamethasone
Drug: Calcipotriol

First Posted Date: 2012-02-22

Last Posted Date: 2025-03-07

Lead Sponsor: LEO Pharma

Target Recruit Count: 303

Registration Number: NCT01536938

Locations: 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸
Altman Dermatology Associates, Arlington Heights, Illinois, United States
🇺🇸
Derm Research Center of New York, Stony Brook, New York, United States

and more 30 locations

Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis

Phase 2

Completed

Conditions: Nail Psoriasis

Interventions: Drug: Indigo Naturalis Extract in Oil
Drug: Calcipotriol Solution

First Posted Date: 2011-10-04

Last Posted Date: 2019-09-10

Lead Sponsor: Yin-ku Lin

Target Recruit Count: 33

Registration Number: NCT01445886

Locations: 🇨🇳
Chang Gung Memorial Hospital, Keelung, Taiwan

LEO 90105 Ointment in Japanese Subjects With Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Dovonex® = calcipotriol
Drug: Rinderon® - DP = betamethasone dipropionate
Drug: LEO 90105 = calcipotriol + betamethasone dipropionate

First Posted Date: 2011-08-24

Last Posted Date: 2025-03-12

Lead Sponsor: LEO Pharma

Target Recruit Count: 676

Registration Number: NCT01422434

Locations: 🇯🇵
Tokai University School of Medicine, Isehara, Kanagawa, Japan

Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

Phase 2

Suspended

Conditions: Psoriasis

Interventions: Other: Vehicle / Placebo
Drug: Calcipotriol Monotherapy
Drug: Nicotinamide Monotherapy
Drug: DPS-102

First Posted Date: 2011-06-08

Last Posted Date: 2011-06-08

Lead Sponsor: DermiPsor, Ltd.

Target Recruit Count: 160

Registration Number: NCT01368887

Locations: 🇺🇸
Boston VA Hospital, Boston, Massachusetts, United States
🇺🇸
Brockton VA Hospital, Brockton, Massachusetts, United States

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Dovonex
Drug: M518101
Drug: placebo

First Posted Date: 2011-02-23

Last Posted Date: 2015-11-05

Lead Sponsor: Maruho Co., Ltd.

Target Recruit Count: 294

Registration Number: NCT01301157

Locations: 🇺🇸
Sierra Medical Research, Fresno, California, United States
🇺🇸
DermResearchCenter of New York, Inc, Stony Brook, New York, United States
🇺🇸
University of Alabama (UAB) Dermatology, Birmingham, Alabama, United States

and more 27 locations

A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris

Phase 1

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: LEO 27989 ointment
Drug: Calcipotriol plus LEO 27989 ointment
Drug: Calcipotriol ointment
Drug: Vehicle ointment

First Posted Date: 2011-02-16

Last Posted Date: 2025-02-24

Lead Sponsor: LEO Pharma

Target Recruit Count: 25

Registration Number: NCT01297166

Locations: 🇫🇷
CPCAD, Nice, France

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Phase 2

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: 0.03% E6201
Drug: 0.005% E6201
Drug: 0.1% E6201
Drug: 0.01% E6201
Drug: 0.05% E6201
Drug: 0.2% E6201
Other: Placebo - 0.03% gel vehicle
Other: Placebo - 0.05% gel vehicle
Other: Placebo - 0.01% gel vehicle
Other: Placebo - 0.1% gel vehicle
Other: Placebo - 0.2% gel vehicle
Drug: Calcipotriene

First Posted Date: 2010-12-31

Last Posted Date: 2021-06-11

Lead Sponsor: Eisai Limited

Target Recruit Count: 30

Registration Number: NCT01268527

Locations: 🇩🇪
Bioskin GmbH, Berlin, Germany

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis

Phase 3

Completed

Conditions: Scalp Psoriasis

Interventions: Drug: Xamiol® gel
Drug: Calcipotriol scalp solution

First Posted Date: 2010-09-06

Last Posted Date: 2025-03-12

Lead Sponsor: LEO Pharma

Target Recruit Count: 244

Registration Number: NCT01195831

Locations: 🇨🇳
Bei Jing Hospital Affiliated Ministry of Health, Beijing, China
🇨🇳
Second Hospital Affiliated to Medical College of Zhe Jiang University, Hangzhou, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy